Evaluation of Local Anesthetic Activity (Surface and Infiltration)

Introduction/Overview

The clinical application of local anesthetics represents a cornerstone of modern medical practice, enabling painless surgical, diagnostic, and therapeutic procedures. The evaluation of local anesthetic activity, specifically for surface (topical) and infiltration anesthesia, is a fundamental pharmacological discipline. This evaluation encompasses not only the assessment of a drug’s ability to produce a reversible blockade of nerve conduction but also a comprehensive understanding of its physicochemical properties, pharmacokinetic behavior, therapeutic utility, and safety profile. Mastery of this topic is essential for the rational and safe use of these agents across numerous medical specialties, including anesthesiology, dentistry, dermatology, emergency medicine, and surgery.

The clinical relevance of this evaluation is profound. Surface anesthesia allows for painless manipulation of mucous membranes and superficial skin lesions, while infiltration anesthesia facilitates minor surgical procedures without the need for systemic sedation or general anesthesia. The importance lies in selecting the appropriate agent, concentration, and formulation to achieve effective analgesia while minimizing local tissue toxicity and systemic adverse effects. An erroneous evaluation can lead to procedural failure, patient discomfort, or serious complications such as systemic local anesthetic toxicity (LAST).

Learning Objectives

• Differentiate between the mechanisms, applications, and formulations of surface anesthesia and infiltration anesthesia.
• Explain the molecular mechanism of action of local anesthetics, including the state-dependent blockade of voltage-gated sodium channels.
• Analyze the relationship between the physicochemical properties of local anesthetics (pK_a, lipid solubility, protein binding) and their pharmacological profiles for surface and infiltration use.
• Evaluate the pharmacokinetic principles governing the onset, duration, and systemic absorption of locally administered anesthetics.
• Identify the common and serious adverse effects, contraindications, and special considerations for the use of local anesthetics in diverse patient populations.

Classification

Local anesthetics are systematically classified based on their chemical structure, which fundamentally influences their pharmacological properties and clinical applications. The primary division is between ester-linked and amide-linked compounds.

Chemical Classification

The chemical linkage between the lipophilic aromatic ring and the hydrophilic amine group serves as the basis for classification. This distinction has critical implications for metabolism, allergic potential, and stability.

Functional Classification for Surface and Infiltration

From a clinical perspective, agents are often categorized by their suitability and common formulations for specific routes of administration.

Agents for Surface Anesthesia: These must possess the ability to penetrate intact keratinized skin or mucous membranes. Efficacy is highly dependent on formulation (e.g., cream, gel, patch, spray, ointment). Common agents include:

• Eutectic Mixture of Local Anesthetics (EMLA): A cream containing a 1:1 oil-in-water emulsion of lidocaine (2.5%) and prilocaine (2.5%). The eutectic mixture has a melting point below room temperature, allowing both drugs to exist in a liquid oil phase that enhances skin penetration.
• Liposomal Lidocaine (4% cream): Uses liposome-encapsulated lidocaine to provide sustained release and prolonged duration of effect.
• Tetracaine: Available in various formulations (e.g., gel, cream) and often combined with other agents for topical use.
• Benzocaine: An ester commonly found in over-the-counter products for mucous membranes (e.g., throat lozenges, teething gels). Its use is limited by the risk of methemoglobinemia, particularly in infants.
• Viscous Lidocaine (2%): A gel formulation used for mucous membranes of the mouth and pharynx.

Agents for Infiltration Anesthesia: These are injected directly into the tissue at the site of the intended procedure. The choice depends on the desired onset and duration of action.

• Short-acting: Procaine, Chloroprocaine.
• Intermediate-acting: Lidocaine, Mepivacaine, Prilocaine.
• Long-acting: Bupivacaine, Ropivacaine, Levobupivacaine.

Mechanism of Action

The fundamental mechanism of action of all local anesthetics is the reversible inhibition of voltage-gated sodium channels (VGSCs) in neuronal cell membranes. This blockade prevents the generation and propagation of action potentials, leading to a loss of sensation in the innervated area.

Molecular and Cellular Basis

Local anesthetics are weak bases, typically existing in equilibrium between a neutral, lipid-soluble free base (B) form and a cationic, water-soluble protonated (BH⁺) form. The proportion is determined by the Henderson-Hasselbalch equation and the agent’s pK_a relative to tissue pH. The free base form is crucial for traversing the lipid bilayer of the neuronal membrane. Once inside the axoplasm, where the pH is lower, the molecule re-equilibrates, and the cationic form predominates.

The active, blocking form of the drug is primarily the cationic species (BH⁺), which binds to a specific receptor site on the α-subunit of the VGSC located on the intracellular side of the channel. This binding site is thought to be within the inner vestibule of the channel pore. Binding physically occludes the pore, preventing sodium ion influx, which is necessary for the depolarization phase of the action potential.

State-Dependent Blockade

Local anesthetics exhibit use-dependent or phasic blockade. Their affinity for the sodium channel receptor is significantly higher when the channel is in an open or inactivated state compared to the resting, closed state. Consequently, rapidly firing neurons (e.g., pain fibers) are blocked more readily and profoundly than slower-firing or resting neurons. This property contributes to the differential blockade observed clinically, where autonomic, pain, and temperature sensations are lost before touch and motor function.

Differential Nerve Blockade

The susceptibility of nerve fibers to local anesthetics is not uniform. In general, smaller diameter fibers (e.g., Type B and C fibers transmitting autonomic and pain/temperature signals) are blocked before larger, heavily myelinated fibers (e.g., Type Aα fibers for motor function). This differential sensitivity is influenced by factors beyond diameter, including firing frequency (as per state-dependent blockade) and the anatomical arrangement of fibers within a nerve bundle. For surface and infiltration anesthesia, the goal is typically to block the small, unmyelinated C fibers and thinly myelinated Aδ fibers responsible for nociception.

Pharmacokinetics

The pharmacokinetic profile of a local anesthetic is a critical determinant of its onset, duration, intensity of effect, and potential for systemic toxicity. For surface and infiltration anesthesia, the processes of absorption and distribution are of paramount importance.

Absorption

The rate and extent of systemic absorption vary dramatically between surface and infiltration administration and are influenced by the vascularity of the application site, the specific drug formulation, and the presence of vasoconstrictors.

Surface Anesthesia: Absorption through skin or mucous membranes is the rate-limiting step for onset. The stratum corneum is a significant barrier. Formulations like EMLA or liposomal lidocaine are designed to enhance penetration. Absorption from highly vascular mucous membranes (e.g., trachea, pharynx) can be rapid and substantial, approaching that of intravenous injection.

Infiltration Anesthesia: Absorption is primarily from the injection site into the systemic circulation. It is directly proportional to the vascularity of the tissue. Injections into highly vascular areas (e.g., head, neck, intercostal space) result in faster and higher peak plasma concentrations (C_max) compared to less vascular areas (e.g., subcutaneous tissue of the trunk or limb).

The addition of a vasoconstrictor, most commonly epinephrine (adrenaline) at concentrations of 1:100,000 to 1:200,000, profoundly alters absorption. By causing local vasoconstriction, epinephrine reduces the rate of vascular uptake from the injection site. This has three major effects: it lowers the peak plasma concentration, reducing the risk of systemic toxicity; it increases the amount of local anesthetic available at the neural target, enhancing the intensity of blockade; and it prolongs the duration of action by slowing removal from the site.

Distribution

After entering the systemic circulation, local anesthetics are distributed throughout body tissues. The initial phase of distribution is rapid to highly perfused organs such as the brain, heart, liver, and kidneys. The volume of distribution (V_d) is generally moderate to high. Highly lipid-soluble agents (e.g., bupivacaine) have a larger V_d. Protein binding, primarily to α₁-acid glycoprotein (AAG), is a key determinant of free, active drug concentration. Agents with high protein binding (e.g., bupivacaine, 95%) have a longer duration of action because less free drug is available for metabolism and elimination.

Metabolism

Metabolic pathways are strictly determined by the chemical class.

• Esters: Undergo rapid hydrolysis in plasma by the enzyme pseudocholinesterase. The rate of metabolism is extremely fast, resulting in short plasma half-lives (e.g., chloroprocaine t_1/2 ≈ 45 seconds). The metabolite para-aminobenzoic acid (PABA) is implicated in allergic reactions.
• Amides: Undergo metabolism in the liver via cytochrome P450-mediated reactions (primarily CYP3A4 and CYP1A2). The process is slower, leading to longer plasma half-lives. For example, lidocaine undergoes N-dealkylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), which may contribute to toxicity. Prilocaine metabolism can produce ortho-toluidine, an oxidant that can cause dose-dependent methemoglobinemia.

Excretion

Renal excretion is the primary route for the elimination of local anesthetic metabolites. Less than 5% of an amide local anesthetic is excreted unchanged in urine. The excretion of ester metabolites is nearly complete via the kidneys. Acidification of urine can enhance the renal clearance of some local anesthetics by ion trapping.

Comparative Pharmacokinetic Parameters

Therapeutic Uses/Clinical Applications

The applications of surface and infiltration anesthesia are extensive and span virtually all medical disciplines. The choice between surface and infiltration techniques depends on the depth of the target nerves, the area to be anesthetized, and the nature of the procedure.

Surface (Topical) Anesthesia

Surface anesthesia is indicated for procedures involving the outermost layers of skin or accessible mucous membranes. It is particularly valuable for minimizing pain associated with needle insertion, minor superficial surgeries, and endoscopic examinations.

• Dermatological Procedures: Curettage of molluscum contagiosum, shave biopsy of skin lesions, laser treatment, tattoo removal, and split-thickness skin graft harvesting. EMLA cream or liposomal lidocaine is applied under an occlusive dressing for 30-60 minutes prior to the procedure.
• Venipuncture and Intravenous Cannulation: Especially in pediatric, anxious, or needle-phobic patients. EMLA or a lidocaine-iontophoresis system can be used.
• Mucous Membrane Anesthesia:
  • Oropharyngeal: Viscous lidocaine for painful mouth ulcers, prior to upper gastrointestinal endoscopy, or laryngoscopy.
  • Ophthalmic: Tetracaine or proparacaine eye drops for tonometry, foreign body removal, or minor corneal procedures.
  • Urethral: Lidocaine jelly for urinary catheterization or cystoscopy.
  • Rectal: Lidocaine ointment for hemorrhoids or prior to anorectal procedures.
• Treatment of Neuropathic Pain: Lidocaine 5% medicated plaster is approved for post-herpetic neuralgia. The plaster provides a high local concentration with minimal systemic absorption.

Infiltration Anesthesia

Infiltration involves the direct injection of local anesthetic into the subcutaneous or intradermal tissue at the surgical site. It is the most common technique for minor office-based surgeries.

• Minor Surgical Procedures: Excision of skin lesions (cysts, lipomas), laceration repair, wound debridement, punch biopsy, and cosmetic procedures.
• Dental Procedures: While nerve blocks are common, infiltration is used for procedures on individual teeth, particularly in the maxilla where bone is more porous.
• As a Supplement to General Anesthesia: Infiltration of the surgical wound at the conclusion of a procedure can provide significant postoperative analgesia, reducing opioid requirements.
• Field Blocks: A ring of infiltration anesthesia surrounding a surgical field, useful for procedures on the scalp, digits, or penis.

Adverse Effects

Adverse effects of local anesthetics can be categorized as local tissue reactions or systemic toxicity. The risk is influenced by dose, site of administration, vascularity, and patient factors.

Local Adverse Effects

• Transient Burning or Stinging on Injection/Application: Common, especially with formulations at a low pH. Buffering lidocaine with sodium bicarbonate (e.g., 1 mL of 8.4% NaHCO₃ per 10 mL of 1% lidocaine) can reduce this discomfort.
• Local Tissue Toxicity: All local anesthetics are potentially myotoxic and neurotoxic at high concentrations. This is rarely a concern at clinical doses used for infiltration but may be relevant with continuous infusions or accidental intrafascicular injection. Preservatives like methylparaben in multi-dose vials may also contribute to local reactions.
• Methemoglobinemia: A specific adverse effect associated primarily with prilocaine and benzocaine. Their metabolites oxidize hemoglobin to methemoglobin, which cannot carry oxygen. Infants and patients with glucose-6-phosphate dehydrogenase deficiency are at higher risk. Treatment involves intravenous methylene blue.

Systemic Adverse Effects

Systemic toxicity occurs when plasma concentrations rise too high, typically due to accidental intravascular injection, excessive dose, or rapid absorption from a highly vascular site. The central nervous system (CNS) and cardiovascular system (CVS) are the primary targets.

• CNS Toxicity: Symptoms follow a dose-dependent progression. Early signs include lightheadedness, perioral numbness, tinnitus, visual disturbances, and restlessness. This can progress to slurred speech, muscular twitching, and overt seizures (tonic-clonic). At very high levels, CNS depression, coma, and respiratory arrest occur. CNS toxicity generally manifests at lower plasma levels than CVS toxicity.
• Cardiovascular Toxicity: Local anesthetics have a depressant effect on cardiac conduction and contractility. They block cardiac sodium channels, leading to decreased automaticity, slowed conduction (prolonged PR and QRS intervals), and reduced contractility. Bupivacaine is particularly cardiotoxic due to its high lipid solubility and strong binding to cardiac sodium channels, which results in a slow dissociation and a high risk of precipitating severe ventricular arrhythmias (e.g., ventricular tachycardia, fibrillation) that are often refractory to treatment.
• Allergic Reactions: True IgE-mediated allergy is rare, especially with amide agents. Most “allergic” reactions are vasovagal responses or reactions to preservatives (methylparaben, metabisulfite in epinephrine-containing solutions) or latex. Ester agents, due to PABA metabolites, have a higher allergenic potential.

Drug Interactions

Significant drug interactions with local anesthetics primarily involve pharmacokinetic alterations or additive pharmacodynamic effects.

Pharmacodynamic Interactions

• Other Sodium Channel Blockers: Concomitant use with other drugs that block cardiac sodium channels (e.g., Class I antiarrhythmics like flecainide, propafenone; tricyclic antidepressants) may have additive cardiotoxic effects, increasing the risk of conduction abnormalities and arrhythmias.
• CNS Depressants: Sedatives, opioids, and general anesthetics may lower the seizure threshold for local anesthetics, potentially making CNS toxicity manifest at lower plasma concentrations.
• Vasoconstrictors: The addition of epinephrine to local anesthetics is a therapeutic interaction. However, systemic absorption of epinephrine can interact with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or non-selective beta-blockers, potentially leading to severe hypertension or arrhythmias.

Pharmacokinetic Interactions

• Enzyme Inducers/Inhibitors: Drugs that induce (e.g., rifampin, phenobarbital) or inhibit (e.g., cimetidine, fluvoxamine) hepatic CYP450 enzymes can alter the metabolism of amide local anesthetics, potentially affecting their duration of action and toxicity profile. Cimetidine can reduce lidocaine clearance, increasing the risk of toxicity.
• Changes in Protein Binding: Conditions or drugs that lower plasma levels of α₁-acid glycoprotein (e.g., severe liver disease) can increase the free fraction of highly protein-bound agents like bupivacaine, potentiating their effect and toxicity.

Contraindications

• Absolute: Known hypersensitivity to the local anesthetic agent or components of its formulation (e.g., methylparaben, metabisulfite). Infection or sepsis at the proposed injection site is a contraindication for infiltration anesthesia.
• Relative: Severe hepatic impairment for amide agents (risk of accumulation). Severe cardiac conduction defects (e.g., high-grade heart block) for agents with cardiotoxic potential. Coagulopathy or anticoagulant therapy increases the risk of hematoma with infiltration. Methemoglobinemia risk factors for prilocaine/benzocaine.

Special Considerations

Pregnancy and Lactation

Local anesthetics are widely used during pregnancy for procedures like dental work, laceration repair, and most importantly, neuraxial labor analgesia. Lidocaine and bupivacaine are generally considered safe when used appropriately. The FDA categorizes most as Category B (animal studies show no risk, but no adequate human studies) or C (risk cannot be ruled out). The key principle is to use the lowest effective dose to minimize fetal exposure. Systemic toxicity in the mother poses a far greater risk to the fetus than the drug itself. During lactation, the amount of local anesthetic excreted in breast milk is clinically insignificant, and their use is not a contraindication to breastfeeding.

Pediatric Considerations

Children have a lower threshold for local anesthetic toxicity due to immaturity of metabolic pathways, decreased levels of plasma proteins (AAG), and a higher cardiac output leading to faster absorption. Dosing must be meticulously calculated on a mg/kg basis. Maximum recommended doses (MRDs) are strictly lower than for adults. For example, the MRD for plain lidocaine is often cited as 4-5 mg/kg, and with epinephrine, 7 mg/kg. Caution is required with topical agents: excessive application of EMLA on large areas or broken skin can lead to systemic absorption, and benzocaine is contraindicated in infants due to methemoglobinemia risk.

Geriatric Considerations

Aging is associated with physiological changes that alter local anesthetic pharmacology. Decreased cardiac output and regional blood flow may slow absorption but also delay elimination. Reduced hepatic blood flow and enzyme activity can decrease the clearance of amide agents. Increased sensitivity to both the therapeutic and toxic effects of local anesthetics may be observed. Lower doses are often sufficient, and careful titration is advised. Age-related decreases in AAG levels can increase the free fraction of protein-bound drugs.

Renal and Hepatic Impairment

Hepatic Impairment: This is a major consideration for amide local anesthetics, as their clearance is dependent on hepatic metabolism. In severe liver disease (e.g., cirrhosis), reduced hepatic blood flow and enzymatic capacity can lead to prolonged half-lives and increased risk of accumulation and toxicity. Dose reduction and extended dosing intervals are necessary. Ester agents, metabolized in plasma, may be preferable in some cases, though reduced pseudocholinesterase activity in advanced liver disease can also prolong their action.

Renal Impairment: Since parent compounds are not significantly renally excreted, renal impairment has minimal direct effect on the pharmacokinetics of most local anesthetics. However, the accumulation of active metabolites (e.g., MEGX and GX from lidocaine) in renal failure could theoretically contribute to toxicity. Furthermore, renal disease often alters plasma protein levels, affecting drug binding.

Summary/Key Points

• Local anesthetics produce reversible nerve conduction blockade by inhibiting voltage-gated sodium channels from the intracellular side, primarily in a use-dependent manner.
• The chemical classification into esters (plasma metabolism) and amides (hepatic metabolism) dictates allergic potential, stability, and pharmacokinetic handling.
• Surface anesthesia requires specialized formulations to penetrate biological barriers and is used for superficial procedures on skin and mucous membranes.
• Infiltration anesthesia involves direct injection into tissue and is the mainstay for minor surgical procedures; its efficacy and safety are enhanced by the addition of vasoconstrictors like epinephrine.
• The onset, intensity, and duration of action are determined by a drug’s physicochemical properties: pK_a (influences onset), lipid solubility (potency), and protein binding (duration).
• Systemic toxicity, primarily affecting the CNS and cardiovascular system, is the most serious adverse effect and is dose-dependent. Bupivacaine carries a particularly high risk of cardiotoxicity.
• Maximum recommended doses must be strictly adhered to, especially in pediatric and geriatric populations, and should be adjusted for patient comorbidities, particularly hepatic impairment.
• Vigilance for signs of intravascular injection (aspiration before injection) and preparedness to manage systemic toxicity (including lipid emulsion therapy) are essential components of safe practice.

Clinical Pearls

• For rapid onset in acidic, infected tissue, choose an agent with a pK_a closest to physiological pH (e.g., lidocaine, pK_a 7.7) over one with a higher pK_a (e.g., bupivacaine, pK_a 8.1).
• When using epinephrine-containing solutions for infiltration in extremities (fingers, toes, penis, ears), exercise extreme caution due to the risk of ischemia from intense vasoconstriction in end-arterial territories.
• Lipid emulsion (20% Intralipid) is the established rescue therapy for severe local anesthetic systemic toxicity (LAST). Its proposed mechanisms include a “lipid sink” effect and direct metabolic support.
• For surface anesthesia on intact skin, application under an occlusive dressing for a sufficient time (≥30 min for EMLA) is critical for adequate dermal penetration and efficacy.
• Always consider the total dose administered across all techniques; toxicity is cumulative.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.